Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines

Samer Hasan Hussein Al Ali1 Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Mothanna Al-Qubaisi2 Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Mohd Zobir Hussein1 Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia;3 Advanced Materials and Nanotechnology Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor, MalaysiaCorrespondence[email protected]

Maznah Ismail2 Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia;4 Department of Nutrition and Dietetics, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Saifullah Bullo1 Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Figures & data

Figure 1 Powder X-ray diffraction patterns of (A) hippuric acid, (B) ZnO, and (C) HAN.

Abbreviations: ZnO, zinc oxide; HAN, hippuric acid nanocomposite.

$Figure 1 Powder X-ray diffraction patterns of (A) hippuric acid, (B) ZnO, and (C) HAN.$

Table 1 IC₅₀ value of different cell lines treated with free doxorubicin or oxaliplatin, and a combination of free drugs with hippuric acid and HAN

Download CSV Display Table

Figure 2 MTT assays of (A) MCF-7, (B) MDA-MB231, and (C) Caco2 cell lines after 72 hours of treatment.

Abbreviations: Dox, doxorubicin; HA, hippuric acid; HAN, hippuric acid nanocomposite; Oxa, oxaliplatin.

Figure 3 Antiproliferative assays of (A) MCF-7, (B) MDA-MB231, and (C) Caco2 cell lines after, 24, 48, and 72 hours of treatment with free doxorubicin or oxaliplatin, and with a combination of doxorubicin or oxaliplatin with hippuric acid and HAN.

Abbreviations: Dox, doxorubicin; HA, hippuric acid; HAN, hippuric acid nanocomposite; Oxa, oxaliplatin.

Table 2 Antiproliferative assays of the MCF-7, MDA-MB231, and Caco2 cell lines after 24, 48, and 72 hours of treatment with free doxorubicin or oxaliplatin, or with the combination of doxorubicin or oxaliplatin with hippuric acid and HAN

Download CSV Display Table

Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines

Table 1 IC₅₀ value of different cell lines treated with free doxorubicin or oxaliplatin, and a combination of free drugs with hippuric acid and HAN

Table 2 Antiproliferative assays of the MCF-7, MDA-MB231, and Caco2 cell lines after 24, 48, and 72 hours of treatment with free doxorubicin or oxaliplatin, or with the combination of doxorubicin or oxaliplatin with hippuric acid and HAN

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines

Figures & data

Table 1 IC50 value of different cell lines treated with free doxorubicin or oxaliplatin, and a combination of free drugs with hippuric acid and HAN

Table 2 Antiproliferative assays of the MCF-7, MDA-MB231, and Caco2 cell lines after 24, 48, and 72 hours of treatment with free doxorubicin or oxaliplatin, or with the combination of doxorubicin or oxaliplatin with hippuric acid and HAN

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1 IC₅₀ value of different cell lines treated with free doxorubicin or oxaliplatin, and a combination of free drugs with hippuric acid and HAN